CIK 0001827087
VIGL Vigil Neuroscience, Inc.
Insider trading from SEC Form 4. Last filing Aug 7, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
12
with a Form 4 at this company
Signals
Open-market buys and sells at Vigil Neuroscience, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 31Weak | Haeberlein Samantha L. Budd director buy | $21k 12,000 shares | - | - | |
| 38Weak | Ivana Magovcevic-Liebisch President and CEO buy | $8,400 5,000 shares | +2% | - | |
| 38Weak | Ivana Magovcevic-Liebisch President and CEO buy | $8,350 5,000 shares | +2% | - | |
| 33Weak | Ivana Magovcevic-Liebisch President and CEO buy | $12k 5,000 shares | +2% | - |
Transactions
The last 88 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 5, 2025 | Atlas Venture Fund XII, L.P. owner | DDisposition to issuer Common Stock | -4,808,896 | - | - | 0 | Aug 7, 2025 |
| Aug 5, 2025 | Atlas Venture Fund XII, L.P. owner | DDisposition to issuer Common Stockindirect: By Atlas Venture Opportunity Fund I, L.P. | -1,027,978 | - | - | 0 | Aug 7, 2025 |
| Aug 5, 2025 | Jennifer Lynn Ziolkowski Chief Financial Officer | DDisposition to issuer Common Stock | -4,000 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Suzanne Louise Bruhn director | DDisposition to issuer Common Stock | -5,000 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Haeberlein Samantha L. Budd director | DDisposition to issuer Common Stock | -5,000 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | David L. F. Gray Chief Science Officer | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -125,000 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Petra Kaufmann Chief Medical Officer | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -144,000 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Gerhard Koenig director | DDisposition to issuer Common Stock | -5,000 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Bruce Booth director | DDisposition to issuer Common Stock | -5,000 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Ivana Magovcevic-Liebisch President and CEO | DDisposition to issuer Common Stock | -222,687 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Stefan Vitorovic director | DDisposition to issuer Common Stock | -5,000 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Mary Thistle director | DDisposition to issuer Common Stock | -5,000 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Cheryl R Blanchard director | DDisposition to issuer Common Stock | -5,000 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Gerhard Koenig director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -18,029 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Ivana Magovcevic-Liebisch President and CEO | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -369,351 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Stefan Vitorovic director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -18,068 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Petra Kaufmann Chief Medical Officer | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -330,000 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | David L. F. Gray Chief Science Officer | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -125,000 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Mary Thistle director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -18,068 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Suzanne Louise Bruhn director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -24,073 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Haeberlein Samantha L. Budd director | DDisposition to issuer Common Stock | -12,000 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Jennifer Lynn Ziolkowski Chief Financial Officer | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -49,968 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Cheryl R Blanchard director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -24,761 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Bruce Booth director | DDisposition to issuer Common Stockindirect: By Atlas Venture Fund XII, L.P. | -4,808,896 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Jennifer Lynn Ziolkowski Chief Financial Officer | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -119,923 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Mary Thistle director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -13,928 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Cheryl R Blanchard director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -24,984 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Ivana Magovcevic-Liebisch President and CEO | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -210,629 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Stefan Vitorovic director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -13,928 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Gerhard Koenig director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -6,954 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Bruce Booth director | DDisposition to issuer Common Stockindirect: By Atlas Venture Opportunity Fund I, L.P. | -1,027,978 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | David L. F. Gray Chief Science Officer | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -267,000 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Suzanne Louise Bruhn director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -18,068 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Haeberlein Samantha L. Budd director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -18,068 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Stefan Vitorovic director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -12,155 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Mary Thistle director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -24,309 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Suzanne Louise Bruhn director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -33,875 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Cheryl R Blanchard director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -36,690 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Ivana Magovcevic-Liebisch President and CEO | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -405,494 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Gerhard Koenig director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -36,690 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Jennifer Lynn Ziolkowski Chief Financial Officer | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -96,051 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Haeberlein Samantha L. Budd director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -13,928 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Bruce Booth director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -7,577 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Jennifer Lynn Ziolkowski Chief Financial Officer | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -21,635 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Gerhard Koenig director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -18,068 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Bruce Booth director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -12,155 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Haeberlein Samantha L. Budd director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -30,694 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Suzanne Louise Bruhn director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -13,928 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Mary Thistle director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -12,155 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Ivana Magovcevic-Liebisch President and CEO | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -43,271 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Cheryl R Blanchard director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -18,068 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Bruce Booth director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -9,713 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Ivana Magovcevic-Liebisch President and CEO | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -282,000 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Suzanne Louise Bruhn director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -24,310 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Cheryl R Blanchard director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -13,928 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Jennifer Lynn Ziolkowski Chief Financial Officer | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -156,000 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Gerhard Koenig director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -13,928 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Gerhard Koenig director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -4,351 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Jennifer Lynn Ziolkowski Chief Financial Officer | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -156,000 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Ivana Magovcevic-Liebisch President and CEO | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -370,000 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Suzanne Louise Bruhn director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -6,235 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Bruce Booth director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -13,928 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Cheryl R Blanchard director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -5,017 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Ivana Magovcevic-Liebisch President and CEO | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -463,000 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Gerhard Koenig director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -12,155 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Bruce Booth director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -34,612 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Jennifer Lynn Ziolkowski Chief Financial Officer | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -110,000 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Cheryl R Blanchard director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -12,155 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Cheryl R Blanchard director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -6,432 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Ivana Magovcevic-Liebisch President and CEO | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -485,000 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Jennifer Lynn Ziolkowski Chief Financial Officer | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -135,000 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Bruce Booth director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -18,068 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | Bruce Booth director | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -48,393 | - | - | 0 | Aug 5, 2025 |
| May 22, 2025 | Cheryl R Blanchard director | AGrant or award Common Stock | +5,000 | $0.00 | $0 | 5,000 | May 23, 2025 |
| May 22, 2025 | Stefan Vitorovic director | AGrant or award Common Stock | +5,000 | $0.00 | $0 | 5,000 | May 23, 2025 |
| May 22, 2025 | Mary Thistle director | AGrant or award Common Stock | +5,000 | $0.00 | $0 | 5,000 | May 23, 2025 |
| May 22, 2025 | Gerhard Koenig director | AGrant or award Common Stock | +5,000 | $0.00 | $0 | 5,000 | May 23, 2025 |
| May 22, 2025 | Haeberlein Samantha L. Budd director | AGrant or award Common Stock | +5,000 | $0.00 | $0 | 17,000 | May 23, 2025 |
| May 22, 2025 | Suzanne Louise Bruhn director | AGrant or award Common Stock | +5,000 | $0.00 | $0 | 5,000 | May 23, 2025 |
| May 22, 2025 | Bruce Booth director | AGrant or award Common Stock | +5,000 | $0.00 | $0 | 5,000 | May 23, 2025 |
| Mar 3, 2025 | Bruce Booth director | AGrant or award Stock Option Award (Right to Buy)derivative | +48,393 | $0.00 | $0 | 48,393 | Mar 4, 2025 |
| Mar 3, 2025 | Suzanne Louise Bruhn director | AGrant or award Stock Option Award (Right to Buy)derivative | +33,875 | $0.00 | $0 | 33,875 | Mar 4, 2025 |
| Mar 3, 2025 | David L. F. Gray Chief Science Officer | AGrant or award Stock Option Award (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Mar 4, 2025 |
| Mar 3, 2025 | Petra Kaufmann Chief Medical Officer | AGrant or award Stock Option Award (Right to Buy)derivative | +144,000 | $0.00 | $0 | 144,000 | Mar 4, 2025 |
| Dec 19, 2024 | Haeberlein Samantha L. Budd director | POpen-market purchase Common Stock | +12,000 | $1.71 | $21k | 12,000 | Dec 19, 2024 |
| Dec 19, 2024 | Ivana Magovcevic-Liebisch President and CEO | POpen-market purchase Common Stock | +5,000 | $1.68 | $8,400 | 222,687 | Dec 19, 2024 |
| Dec 18, 2024 | Ivana Magovcevic-Liebisch President and CEO | POpen-market purchase Common Stock | +5,000 | $1.67 | $8,350 | 217,687 | Dec 18, 2024 |
| Dec 5, 2024 | Ivana Magovcevic-Liebisch President and CEO | POpen-market purchase Common Stock | +5,000 | $2.34 | $12k | 212,687 | Dec 5, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Atlas Venture Fund XII, L.P.owner
- Cheryl R Blanchardceo, president, officer, director
- Bruce Boothdirector
- Suzanne Louise Bruhndirector
- Haeberlein Samantha L. Budddirector
- David L. F. GrayChief Science Officer
- Petra KaufmannChief Medical Officer
- Gerhard Koenigdirector
- Ivana Magovcevic-LiebischPresident and CEO
- Mary Thistledirector
- Stefan Vitorovicdirector
- Jennifer Lynn ZiolkowskiChief Financial Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.